Möchten Sie immer auf dem neuesten Stand bleiben?

PHILADELPHIA, Pennsylvania and COPENHAGEN, Denmark, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Alveus Therapeutics, Inc. (“Alveus”), a clinical-stage biotechnology company developing next-generation...

FDA Granted Hopstem’s hNPC01 for Chronic Ischemic Stroke Approval to Enter Phase 2/3 Adaptive Pivotal Clinical Trial with Bridging Study

SPARK NS and Haukeland University Hospital Announce Clinical Trial of D-Serine for Modifying Parkinson’s Disease Progression

BOSTON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- BPGbio, Inc., a leading biology-first, AI-powered clinical-stage biopharma company, today announced that the U.S. Food and Drug Administration (FDA) has...

Lynch Syndrome (LS) is a common hereditary condition that significantly increases the lifetime risk of developing multiple cancersNOUS-209 is an off-the-shelf cancer immunotherapy designed to induce...

In this update, Mr. Nathanielsz highlights the significant progress achieved during 2025 and outlines the Company’s ambitious plans for 2026.

SINGAPORE, Jan. 13, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on...

Tisento's global Phase 2b PRIZM study, which is evaluating zagociguat for the treatment of the rare mitochondrial disease MELAS, is fully enrolled

Herantis Pharma Plc – Company release Inside information: Herantis Pharma – Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson's disease Biomarker...

PridCor Therapeutics advances its SHIELD Long COVID study with a peer-reviewed publication and FDA confirmation of IND exemption.